Literature DB >> 29564164

rpsftm: An R Package for Rank Preserving Structural Failure Time Models.

Annabel Allison1, Ian R White2, Simon Bond3.   

Abstract

Treatment switching in a randomised controlled trial occurs when participants change from their randomised treatment to the other trial treatment during the study. Failure to account for treatment switching in the analysis (i.e. by performing a standard intention-to-treat analysis) can lead to biased estimates of treatment efficacy. The rank preserving structural failure time model (RPSFTM) is a method used to adjust for treatment switching in trials with survival outcomes. The RPSFTM is due to Robins and Tsiatis (1991) and has been developed by White et al. (1997, 1999). The method is randomisation based and uses only the randomised treatment group, observed event times, and treatment history in order to estimate a causal treatment effect. The treatment effect, ψ, is estimated by balancing counter-factual event times (that would be observed if no treatment were received) between treatment groups. G-estimation is used to find the value of ψ such that a test statistic Z(ψ) = 0. This is usually the test statistic used in the intention-to-treat analysis, for example, the log rank test statistic. We present an R package that implements the method of rpsftm.

Entities:  

Year:  2017        PMID: 29564164      PMCID: PMC5858764     

Source DB:  PubMed          Journal:  R J        ISSN: 2073-4859            Impact factor:   3.984


  8 in total

1.  Randomization-based methods for correcting for treatment changes: examples from the Concorde trial.

Authors:  I R White; A G Babiker; S Walker; J H Darbyshire
Journal:  Stat Med       Date:  1999-10-15       Impact factor: 2.373

2.  Impact of treatment changes on the interpretation of the Concorde trial.

Authors:  I R White; S Walker; A G Babiker; J H Darbyshire
Journal:  AIDS       Date:  1997-07       Impact factor: 4.177

3.  Uses and limitations of randomization-based efficacy estimators.

Authors:  Ian R White
Journal:  Stat Methods Med Res       Date:  2005-08       Impact factor: 3.021

4.  Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee.

Authors: 
Journal:  Lancet       Date:  1994-04-09       Impact factor: 79.321

5.  TREATMENT SWITCHING: STATISTICAL AND DECISION-MAKING CHALLENGES AND APPROACHES.

Authors:  Nicholas R Latimer; Chris Henshall; Uwe Siebert; Helen Bell
Journal:  Int J Technol Assess Health Care       Date:  2016-01       Impact factor: 2.188

6.  Adjusting for treatment switching in randomised controlled trials - A simulation study and a simplified two-stage method.

Authors:  Nicholas R Latimer; K R Abrams; P C Lambert; M J Crowther; A J Wailoo; J P Morden; R L Akehurst; M J Campbell
Journal:  Stat Methods Med Res       Date:  2014-11-21       Impact factor: 3.021

7.  Adjusting overall survival for treatment switches: commonly used methods and practical application.

Authors:  Claire Watkins; Xin Huang; Nicholas Latimer; Yiyun Tang; Elaine J Wright
Journal:  Pharm Stat       Date:  2013-10-18       Impact factor: 1.894

Review 8.  Nonadherence to treatment protocol in published randomised controlled trials: a review.

Authors:  Susanna Dodd; Ian R White; Paula Williamson
Journal:  Trials       Date:  2012-06-18       Impact factor: 2.279

  8 in total
  5 in total

1.  A randomized placebo-controlled trial of vitamin D supplementation for reduction of mortality and cancer: Statistical analysis plan for the D-Health Trial.

Authors:  Mary Waterhouse; Dallas R English; Bruce K Armstrong; Catherine Baxter; Briony Duarte Romero; Peter R Ebeling; Gunter Hartel; Michael G Kimlin; Donald S A McLeod; Rachel L O'Connell; Jolieke C van der Pols; Alison J Venn; Penelope M Webb; David C Whiteman; Rachel E Neale
Journal:  Contemp Clin Trials Commun       Date:  2019-02-20

2.  Using generalized linear models to implement g-estimation for survival data with time-varying confounding.

Authors:  Shaun R Seaman; Ruth H Keogh; Oliver Dukes; Stijn Vansteelandt
Journal:  Stat Med       Date:  2021-05-04       Impact factor: 2.373

3.  Statistical methods for non-adherence in non-inferiority trials: useful and used? A systematic review.

Authors:  Matthew Dodd; Katherine Fielding; James R Carpenter; Jennifer A Thompson; Diana Elbourne
Journal:  BMJ Open       Date:  2022-01-12       Impact factor: 2.692

4.  Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Authors:  Rachel Evans; Neil Hawkins; Pascale Dequen-O'Byrne; Charles McCrea; Dominic Muston; Christopher Gresty; Sameer R Ghate; Lin Fan; Robert Hettle; Keith R Abrams; Johann de Bono; Maha Hussain; Neeraj Agarwal
Journal:  Target Oncol       Date:  2021-09-03       Impact factor: 4.493

5.  Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.

Authors:  T K Choueiri; R J Motzer; B I Rini; J Haanen; M T Campbell; B Venugopal; C Kollmannsberger; G Gravis-Mescam; M Uemura; J L Lee; M-O Grimm; H Gurney; M Schmidinger; J Larkin; M B Atkins; S K Pal; J Wang; M Mariani; S Krishnaswami; P Cislo; A Chudnovsky; C Fowst; B Huang; A di Pietro; L Albiges
Journal:  Ann Oncol       Date:  2020-04-25       Impact factor: 32.976

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.